BofA reiterates Regeneron stock rating after melanoma trial miss By Investing.com

Regeneron’s phase 3 fianlimab/cemiplimab melanoma trial missed its primary endpoint despite median progression-free survival of 11.5 months versus 6.4 months for pembrolizumab. BofA Securities reiterated a Buy rating and $860 price target, implying about 23% upside from $698.25, and said any share weakness could be a buying opportunity. The article also notes recent target cuts from Truist to $769 and Raymond James to $902 amid mixed read-throughs from Dupixent strength and Eylea HD weakness.

Analysis

The market is treating the melanoma readout as a binary loss, but the bigger signal is that REGN’s near-term multiple should not be anchored to any single oncology option. The company’s cash-generative core still looks underappreciated versus peers because the market is pricing a persistent pipeline disappointment discount, yet the data suggest that discount may already be too large if Dupixent can continue offsetting Eylea normalization over the next 2-4 quarters.

Competitively, the setback likely helps incumbents with more established checkpoint franchises and hurts the perceived viability of LAG-3 follow-on programs, especially smaller biotech names that were hoping to re-rate on mechanism validation. The second-order effect is on capital allocation: if management and investors conclude oncology is optionality rather than a pillar, the stock can rerate on improved buyback/dividend credibility and on reduced pipeline spend drag rather than on headline trial success.

The main risk is not the failed endpoint itself, but whether investors extrapolate one miss into a broader thesis that the growth engine is structurally slowing. That risk should fade over 30-90 days if the next update cycle reinforces Dupixent durability and Eylea HD inventory normalization. Conversely, if ophthalmology prints remain soft into the next quarter, the market will likely keep REGN in a “show-me” box and compress the multiple further despite solid execution elsewhere.

Contrarian view: the selloff may be overdone because the incremental downside from this program was always limited, while the upside from a clean win was already capped by high expectations. The market may be underestimating how quickly the stock can recover once attention shifts back to the core franchise mix, especially if management uses weakness to signal more aggressive capital returns.

Key Decisions for Investors

• Buy REGN on weakness in the next 1-3 sessions if the stock trades down another 2-4% from current levels; target a 8-12% rebound over 4-8 weeks as the event discount fades and the market refocuses on core earnings power. Tight stop if follow-up commentary implies broader pipeline de-risking is now in doubt.
• Pair trade: long REGN / short a basket of LAG-3-dependent biotech names over the next 1-2 months. The thesis is that this readout removes mechanism validation from the ecosystem and should compress weaker names more than REGN, which has multiple independent value drivers.
• Use REGN Jan-2026 call spreads to express recovery upside with defined risk. A structure around current spot should capture a re-rating if the stock returns to the prior 52-week range, while limiting loss if ophthalmology softening persists.
• For relative value, prefer SNY over REGN on a 3-6 month horizon if you want cleaner exposure to Dupixent without the oncology overhang. The spread works if the market continues rewarding visible growth and penalizing pipeline uncertainty.